anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses novel signaling pathways controlling the pathogenesis of the human respiratory bacterium,  Haemophilus influenzae.  The lipooligosaccharide-phosphorylycholine (LOS-PC) cell surface epitope of  H. influenzae  enhances pathogenesis but also increases bacterial susceptibility to innate and adaptive immunity and the administration of therapeutic compounds. Modulation of the LOS-PC epitope may be affected by an interaction between environmental conditions (i.e., for example, oxygen tension) and genetic regulation of precursor biosynthetic pathway activity. LOS-PC epitope display increases under microaerobic conditions and decreases under aerobic conditions. This is consisent with a bacteria's propensity to initiate pathogensis under low oxygen conditions. Pathogenesis may be prevented by disrupting the role of the putative  H. influenzae  homologue of CsrA, that downregulates galU expression. Disrupting CsrA repression of galU expression resulted in increased LOS-PC epitope display.
Relapse to drug abuse often happens in the presence of stimuli that are associated with previous drug-use, and drug-taking behavior appears to be partly controlled by such cues. While some theories postulate that such facilitation is mediated by cue-induced craving states, others hypothesize that the underlying processes are highly automatized and can happen without conscious control or even awareness. One way to approach psychological mechanisms of cue reactivity is to measure disruption of ongoing mental activity by drug-related material in dependent individuals while manipulating the degree to which cognitive evaluative processes can unfold. Craving measurement under these conditions can elucidate its relationship with automatic processing versus conscious evaluation of drug cues. Autonomic and neural correlates can be identified by concomitant psychophysiological and fMRI recording. Results from these studies will shed light on the role of spontaneous automatic reactions versus cognitive evaluation for different measures of cue reactivity. By helping to elucidate the psychological mechanisms and neurobiological basis of drug-cue reactivity in dependent individuals, this may have substantial implications for the understanding of mechanisms and treatment of drug dependence. Thus, while there are no direct benefits to subjects participating in these experiments, the results may benefit the health of society. MRI-related risks to subjects (injury from metal implants, claustrophobia, temporary deafness due to the loud banging noises) will be minimized by prescreening and providing earplugs. Drug-related cues may induce acute craving; subjects will be dismissed only after craving levels have returned to baseline.
A dosage form, resembling a granulate, for solid pharmaceuticals (I) consists of individual particles prepd. from powdered (I) by conventional compression to small tablets. Pref. the powder is subjected to fine sieving before compression. This dosage form is more widely applicable than normal granules and avoids the difficulties associated with tablets and dragees. Since the individual particles are small the active ingredient is generally released quickly (although enteric coatings may be applied); they can be measured out by vol., wt. or number, are extremely strong and can be coated e.g. by spraying, or filled into capsules. A specific application is for dry organ preparations, extracts or concentrates used in enzyme substitution therapy of the digestive tract.
Single injection of rFVIIIFc (current 2K scale) followed by 2 single injections of rFVIIIFc (15K scale) 1000 IU vial at PK2 and PK3 timepoints. Participants will be on prophylaxis regimen along with treatment for bleeding episodes for 26 weeks of treatment period using the rFVIIIFc (15K scale) 1000 IU vial.
Prepare ALDURAZYME using low-protein-binding containers. There is no information on the compatibility of diluted ALDURAZYME with glass containers. Dilute ALDURAZYME in the following manner using aseptic technique:

  1. Determine the infusion bag volume and number of ALDURAZYME vials to be diluted based on actual body weight in kg and the recommended dose [see Dosage and Administration (2.2)]. Round the number of vials up to the next whole number.
  2. Remove the appropriate number of ALDURAZYME vials from the refrigerator and allow the vials to reach room temperature 20°C to 25°C (68°F to 77°F) before use. Do not heat or microwave the vials.
  3. Visually inspect the solution in each vial for particulate matter and discoloration. The ALDURAZYME solution should be clear to slightly opalescent and colorless to pale yellow. Some translucency may be present in the solution. Discard if the solution is discolored or if visible particulate matter is present.
  4. Withdraw and discard a volume of the 0.9% Sodium Chloride Injection from an infusion bag, equal to the volume of ALDURAZYME to be added.
  5. Slowly withdraw the calculated volume of ALDURAZYME from the appropriate number of vials using caution to avoid excessive agitation. Do not use a filter needle, as this may cause agitation. Agitation may denature ALDURAZYME, rendering it biologically inactive. Discard any unused solution remaining in the vial.
  6. Slowly add the ALDURAZYME solution to the 0.9% Sodium Chloride Injection solution through the port of the infusion bag and avoid agitation. Do not use a filter needle.
  7. Gently rotate the infusion bag to ensure proper distribution of ALDURAZYME. Do not shake the infusion bag.
NEW MATERIAL:A hepatic cell growth factor consisting of a substance having the following physiochemical properties and physiological activity. The substance has a mol.wt. of approximately 18,000 by a SDS-polyacrylic amide gel electrophoresis, is adsorbed on heparin sepharose and eluted in a NaCl concentration of 1.9-2,0 M and has a hepatic cell growth activity. USE:A remedy for hepatic diseases such as acute hepatitis, fulminant hepatitis, chronic hepatitis and cirrhosis. PREPARATION:For example, a spleen is cut off from a cattle, ground in a buffer solution and centrifuged. The supernatant is dialyzed in a 10mM phosphoric acid buffer solution and subjected to an ion exchange column chromatography. The non-adsorbed fractions are treated with an immobilized heparin column and adsorbed substances are eluted. An active fraction is applied to a hydroxy apatite column, and adsorbed substances are eluted. The eluted substances are treated with a heparin-immobilized column and the adsorbed substance is eluted to provide the hepatic cell growth factor.
Healthy Japanese adult males will receive 1 of 3 single oral doses of CCX168 (10 mg, 30 mg or 100 mg) or placebo. Each dose level will be administered under fasted conditions. Single doses of CCX168 30 mg will be administered under fasted and fed conditions.
Zolmitriptan Nasal Spray, USP contains zolmitriptan, which is a selective 5-hydroxytryptamine 1B/1D (5-HT1B/1D) receptor agonist. Zolmitriptan is chemically designated as (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone and has the following chemical structure:

The empirical formula is C16H21N3O2, representing a molecular weight of 287.36. Zolmitriptan is a white to almost white powder that is readily soluble in water. Zolmitriptan Nasal Spray is supplied as a clear to pale yellow solution of zolmitriptan, buffered to a pH 5.0. Each Zolmitriptan Nasal Spray contains 2.5 mg or 5 mg of zolmitriptan in a 100-μL unit dose aqueous buffered solution containing citric acid, anhydrous, USP, disodium phosphate dodecahydrate USP, benzalkonium chloride solution NF and purified water USP.

Zolmitriptan Nasal Spray is hypertonic. The osmolarity of Zolmitriptan Nasal Spray for 2.5 mg is 358 to 396 mOsmol, and for 5 mg is 411 to 455 mOsmol.
PURPOSE:To provide the title agent unforcedly giving dietetic effect through its routine taking, comprising a low-molecular peptide composition obtained by hydrolysis of protein using an enzyme. CONSTITUTION:The objective dietetic agent comprising a low-molecular peptide composition 200-550 in average molecular weight which can be obtained by hydrolysis at 40-60 deg.C for 18-48hr of protein derived from animals, plants or microorganisms (pref. lactoprotein or soybean protein) using an enzyme (pref. endoprotease active in neutral pH region). This composition consists mainly of dipeptides and tripeptides containing <=20wt.% of peptides with a molecular weight of >=700 and also containing <=5wt.% of free amino acids. The present dietetic agent is effective for suppressing body weight and fat accumulation.
Growth disturbances of the temporomandibular Joint are characterized by mandibular asymmetry, sometimes with secondary maxillar disturbances. Although the clinical symptoms are sometimes quite severe, patients usually have no pain. There are several growth disturbances, but in this article we discuss three particular causes of facial asymmetry, namely hemimandibular growth defects; overdevelopment, underdevelopment and neoplasms of the mandibular joint. Hemimandibular overdevelopment (hyperplasia) is a growth disorder characterized by progressive asymmetry of the mandibula. Hemimandibular hypoplasia, on the other hand, is a growth disorder involving underdevelopment of the condyle mandibulae due to impingement of the growth center and ankylosing. A pronounced asymmetrical face can cause aesthetic problems and always requires diagnostics, because in addition to the hyperplasia and hypoplasia mentioned above, other causes can explain the asymmetry such as, for example, an osteoarthritis or even a tumor emanating from the base of the skull, mandibula or soft tissues.
PCT No. PCT/FR95/00140 Sec. 371 Date Nov. 7, 1996 Sec. 102(e) Date Nov. 7, 1996 PCT Filed Feb. 6, 1995 PCT Pub. No. WO95/21791 PCT Pub. Date Aug. 17, 1995Alkaline-earth metal- and copper- and optionally titanium-based silicates in the form of agglomerates consisting either of monocrystalline grains or of aggregates themselves consisting of monocrystalline particles. These silicates are prepared by a process including the following stages: a silica sol or a silicate and optionally a titanium sol is mixed with salts of the other constituent elements of the silicate with the exception of oxygen; the mixture thus obtained is dried, preferably by spraying, and the product obtained is calcined. The silicates may be employed as colored pigments in plastics, paints, varnishes, rubbers, ceramics, glazes, papers, inks, cosmetic products, dyes and laminated coatings.
BACKGROUND Extracorporeal shockwave lithotripsy (ESWL) is a common procedure, and splenic rupture is a rare complication of ESWL. Depending on the stage of injury and patient's condition, treatment options include non-operative management (NOM) and emergency splenectomy. Diagnosis is not difficult with symptoms such as deteriorating hemodynamic and hematologic indices, localized physical signs of peritoneal irritation in the left hypochondriac region, and confirmation provided by signs of free fluid (hemoperitoneum) seen on ultrasound or computed tomography (CT). Prompt diagnosis and treatment are essential for patient survival. If NOM is not feasible, emergency laparotomy with splenectomy is standard procedure. CASE REPORT A 72-year-old man with a medical history of arterial hypertension and cardiac arrhythmia was emergently admitted 1 day after undergoing ESWL for bilateral nephrolithiasis. He presented with abdominal pain, nausea, vomiting, and anemia. Urgent CT confirmed a splenic rupture, with intraperitoneal fluid. He underwent emergency splenectomy 24 h after ESWL. Complete splenic rupture (grade IV) was identified, accompanied by significant blood loss of 2000 mL. The postoperative course was uneventful, and he was discharged on postoperative day 7, with primary wound healing. CONCLUSIONS Splenic injury following ESWL is a rare but serious complication. Our case underscores the importance of monitoring for splenic injury following ESWL. Management should be multidisciplinary, considering physiological, anatomical, and immunological aspects. While splenectomy is the standard treatment, NOM can be considered for hemodynamically stable patients to avoid complications following splenectomy. Recent treatment protocols have improved stone breakage and reduced tissue damage, suggesting long-term adverse effects can be minimized or eliminated.
Peace-Building Intervention Process- The intervention process consists of eight sessions and adheres to a manualized protocol that we developed. Each session lasts 120 minutes.
The study will be conducted at the CHU Brugmann Hospital, with collaboration between cardiac surgery and cardiology wards. Subjects referred for non valvular cardiac surgery will be prospectively included during the first 6 months following the onset of the protocol.
Every third month, a dental nurse will visit at home and deliver professional dental cleaning and delivery of one new toothbrush and fluoride toothpaste (\>4000ppm) (n:3) for the next three months. The visit is expected to take at the most 30 minutes.
Dual Blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on Lotensin and other agents that affect the RAS.

Do not coadminister aliskiren with Lotensin in patients with diabetes. Avoid use of aliskiren with Lotensin in patients with renal impairment (GFR < 60 mL/min).
OBJECTIVE: The aim of this study was to describe the quality of life (QoL) of children with a chronic illness treated in a tertiary multidisciplinary pediatric department in comparison with the general population.
STUDY DESIGN: A cross-sectional study was conducted in the tertiary multidisciplinary (nephrology, hepatogastroenterology, endocrinology, diabetology, transplantation) pediatric department of Timone Hospital in Marseille, France. Patients 8-17 years of age with a chronic disease were included during regular follow-up appointments. Medical and sociodemographic variables were obtained from medical records. Self-reported QoL was assessed using the VSPA (Vécu et Santé Perçu de l'Adolescent) questionnaire and parent-reported QoL was assessed using the VSPA questionnaire for parents.
RESULTS: A total of 244 patients were included. Overall QoL did not differ significantly from that of the general population. Adolescent patients' self-reported QoL scores were lower than those of the general population in the domains of physical health and leisure, and parents reported QoL scores for adolescent patients lower than those of the general population for self-esteem and physical health. Adolescents' self-reported QoL scores were higher than in the general population for relationships with parents, healthcare professionals, and teachers as well as for school achievement. Parents also reported higher QoL scores in these areas for their children.
CONCLUSION: Children and adolescents with a variety of chronic diseases had similar overall QoL scores to the general population but with different QoL profiles; their scores in some domains were higher than those of the general population.
FIELD: medicine, allergology, immunology. SUBSTANCE: method involves purification of allergens by gel-filtration method, isolation of protein fraction, sensitization of formalized tannized ram erythrocytes, standardization using photoelectrocolorimeter up to 3%, evaluation of activity and specificity by indirect method of fluorescent antibodies and stabilization by lyophilic drying. Invention provides preparing standard, active, specific, stable in storage of corpuscularized diagnostica. Invention can be used for production of diagnostic preparations based on insoluble carriers. EFFECT: improved preparing method. 2 cl
PURPOSE:To provide the titled complex consisting of hepatitis virus B surface antigen (HBsAg) bonded with a polysaccharide and capable of giving an HB vaccine having high titer. CONSTITUTION:A polysaccharide (having a molecular weight of about 1,000-100,000; e.g. dextran, cellulose, hydroxyethyl cellulose, agarose, starch, chondroitin sulfate, arginic acid, etc.) is activated (e.g. by covalent bond method, scission of aldohexo-pyranose ring of polysaccharide, linking of bifunctional compound, etc.) and the activated polysaccharide is bonded with HBsAg directly or interposing a 1-3C chain molecule to obtain the objective complex. The molecular weight of the complex is useful as a drug such as hepatitis B vaccine, etc., and diagnostic reagent, etc.
The invention is a pastille consisting of coated chewable gum, which controls a chemical process for rendering teeth more resistant to tooth decay. The pastille has a coating which is soluble in the oral environment and releases fluoride ions while dissolving, and the body consisting of a flavoured chewable gum formulated in such a way as to be capable of releasing calcium ions. The fluoride ions, which are released as the coating of the pastille dissolves in the mouth, permeate the surfaces of the teeth. The mastication of the gum subsequently releases the calcium ions, from a variety of calcium salts mixed into the gum. The released calcium ions consequently react with the fluoride ions which were previously permeated into the teeth to form calcium fluoride precipitate, and other calcium-fluoride compounds in the teeth and on the surface of the teeth, which render the teeth more resistant to attack by bacterially produced acids. Thus making them more resistant to tooth decay.
BACKGROUND: Some patients with viral encephalitis in China seek treatment with Chinese patent medicine (CPM) to improve their symptoms, but few studies have focused on the impact of CPM on the prognosis of viral encephalitis (VE). The aim of this multicenter retrospective study was to assess the benefit of adjunctive CPM therapy on the outcome of children with VE in China.
METHODS: This study retrospectively included 834 children with viral encephalitis who were hospitalized at five medical institutions from 2018 to 2021. Univariate and multivariate logistic regression was used to assess the effect of CPM on sequelae in patients with VE. 1:1 propensity score matching was used to exclude the effect of confounding factors. Forest plots were used to observe the effect of CPM on the prognosis of VE in different subgroups.
RESULTS: There were fewer patients with sequelae in the group of patients using CPM regardless of whether they were matched or not. The results of multivariate logistic regression analysis showed that the use of CPM was an independent protective factor for the development of sequelae in VE patients (OR = 0.063, 95 % CI: 0.011-0.350, p = 0.002). Subgroup analyses showed that CPM was a protective factor for the development of sequelae regardless of the presence or absence of coma and comorbidities. In addition, we evaluated other outcome indicators and found shorter duration of illness, fever and headache in children with EV in the CPM group.
CONCLUSION: Adjunctive CPM therapy may significantly reduce sequelae in children with VE, as well as effectively alleviate patients' clinical symptoms. However, more prospective studies and clinical trials are needed to further evaluate its efficacy and safety.
The invention discloses grass bead essential oil and a preparation method thereof. The solubility of the procyanidin is improved by the fat-soluble procyanidin acetone condensation compound. The antioxidant and anti-aging effects are added to the essential oil, and the moisturizing effect of the grass bead essential oil is enhanced. The hyaluronic acid glyceryl monostearate derivative with amphiphilicity forms a weak network structure in the grass bead essential oil, enhances the structural strength of the essential oil, can be combined with skin more firmly, and directly increases the effect of the essential oil. Phospholipid in the cell membrane can identify phosphorus element more quickly, and phosphoric acid ceramide acidified by phosphoric acid can act on epidermal cells more quickly, so that the effect of quickly preserving moisture is achieved. The essential oil moisturizing effect is enhanced by improving the basis of the grass beads.
Methods are provided for locally administering an agent to a host. Specifically, the subject methods provide for the local administration of an agent to an interstitial space of a host. In the subject methods, an agent is retroinfused into a vessel of a host, typically a vein, under conditions sufficient for the agent to enter an interstitial space of the host proximal to the vessel location into which the agent is retroinfused. In practising the subject methods, the agent is administered to the host in combination with the production of vascular stress upstream of the site of administration and adjacent to the target interstitium, where the vascular tissue stress is sufficient to provide for transport of the agent from the vascular site of deposition into the target interstitial space. In a preferred embodiment, the agent is retroinfused at a pressure sufficient to provide for mechanical stress on the vessel proximal to the target interstitial space. Also provided are kits for use in practising the subject methods. The subject invention finds use in the local administration of a variety of different agents for treatment of a variety of different disease or other conditions.
The aim of this study was to investigate the trend in the prevalence of overweight and obese adults in São Paulo, Brazil, between 2006 and 2019 across chronic diseases and the domains of physical activity. A descriptive retrospective study was carried out on the trend in the prevalence of 26.612 overweight and obese adults (10.150 men and 16.462 women). All data analyzed were based on information from the national system for monitoring risk factors called Protective and Risk Factors for Chronic Diseases by Telephone Survey-VIGITEL. The variables obese and overweight were analyzed in general and stratified by sex, age group, education level, each type of physical activity domain (yes or no), presence of hypertension and diabetes (yes or no), and smoking (yes or no). The prevalence of obesity significantly increased from 11.1% in 2006 to 19.8% in 2019, regardless of age, sex, physical activity practice, and presence of diabetes or hypertension, except for people aged 55-64 y, working people, and smokers. The total prevalence of overweight adults significantly increased overall (from 30.5% in 2006 to 33.4% in 2019) but it significantly increased only in females, in people aged 18-24 y, those who are non-white, those with an education level of 9-11 y, those who are not working, those who are non-smokers, those who did not have diabetes or hypertension, and those who were not physically active during leisure time but physically active at work and at home. There was a significant increase in the prevalence of overweight adults and especially of obese adults living in the city of São Paulo (Brazil) between 2006 and 2019, the latter being observed in nearly every analyzed sub-category, regardless of age, sex, physical activity practice, and presence of diabetes or hypertension.